Andere Sprachen Carisma Therapeutics, Inc.

Aktien

A3DZG2

US14216R1014

CARM

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
1.64 ^USD	0.00%		+0.61%	-44.03%

11.04.	CARISMA THERAPEUTICS, INC. : Kaufen-Bewertung von BTIG	ZM
02.04.	CARISMA THERAPEUTICS, INC. : HC Wainwright behält die Bewertung Kaufen bei	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy Annual Meeting	23.04.
Carisma Therapeutics to Present at Upcoming Conferences	03.04.
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	02.04.
Carisma Therapeutics Q4 Net Loss Narrows, Revenue Rises; Plans Job Cuts in Q2 -- Shares Decline	01.04.
Carisma Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
Carisma Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01.04.
Carisma Therapeutics Announces Changes to its Board of Directors	01.04.
Carisma Therapeutics, Inc. Announces Changes to Its Board of Directors	01.04.
North American Morning Briefing : Stock Futures -2-	19.03.
North American Morning Briefing : Inflation Data -2-	12.03.
Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference	28.02.
Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	21.12.
Carisma Therapeutics' First Lead Candidate Under Moderna Deal to Target Cancer Treatment	14.12.
Carisma Therapeutics Obtains FDA Clearance to Study Potential Solid Tumor Therapy	28.11.
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte	28.11.
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte	28.11.
Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference	22.11.
Carisma Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.
North American Morning Briefing : Stocks Look to -2-	06.11.
Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC	01.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Carisma Therapeutics, Inc.

Aktien

A3DZG2

US14216R1014

CARM

Andere Sprachen

Filter